FDG PET/CT imaging suggests lymphoma involving prostate may be more resistant to treatment

Clin Nucl Med. 2011 Mar;36(3):255-7. doi: 10.1097/RLU.0b013e3181f9e012.

Abstract

FDG PET imaging is generally not useful for prostate cancer. Nevertheless, incidental intense FDG uptake in the prostate warrants further evaluation to assess for prostatic malignancy. We report a case where intense FDG uptake was incidentally noted in an enlarged prostate on FDG PET/CT scan performed for a large left hilar/mediastinal mass (that was also intensely FDG avid along with several additional FDG-avid lesions elsewhere). Biopsy of the prostate and mediastinal lesions revealed large B-cell non-Hodgkin lymphoma at both sites. Serial FDG PET/CT imaging in this patient revealed that the prostatic lymphomatous lesions showed a slower and incomplete response to chemotherapy compared with other sites of lymphomatous involvement (that showed a rapid and complete response to chemotherapy) in the same patient.

Publication types

  • Case Reports

MeSH terms

  • Drug Resistance, Neoplasm*
  • Fluorodeoxyglucose F18*
  • Humans
  • Lymphoma / diagnostic imaging
  • Lymphoma / drug therapy*
  • Male
  • Middle Aged
  • Positron-Emission Tomography*
  • Prostate / diagnostic imaging*
  • Prostate / pathology
  • Tomography, X-Ray Computed*

Substances

  • Fluorodeoxyglucose F18